ALK7 Binding Proteins and Uses Thereof
AssigneeAcceleron Pharma Inc.
InventorsJohn Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
Life of this patent
Estimating the term…
Loading patent…
AssigneeAcceleron Pharma Inc.
InventorsJohn Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
Estimating the term…
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
An activin receptor-Like Kinase 7 (ALK7)-binding protein comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:128 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:135,
2-45. (canceled)
An isolated ALK7-binding protein comprising a set of CDRs in which:
Dependencies are inferred from the claim text.